San Diego, CA -- (SBWIRE) -- 11/29/2016 -- An investigation on behalf of investors of Endologix, Inc. (NASDAQ:ELGX) shares over potential securities laws violations by Endologix in connection certain financial statements was announced.
Investors who purchased shares of Endologix, Inc. (NASDAQ:ELGX), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Endologix, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On August 2, 2016, CEO John McDermott indicated that Endologix, Inc would seek approval of the original version of the Nellix system that was used in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study, given that Endologix, Inc had the needed clinical data.
On November 16, 2016, Endologix, Inc announced that the FDA has requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix.
Shares of Endologix, Inc. (NASDAQ:ELGX) declined to as low as $6.22 per share on November 16, 2016.
On November 28, 2016, NASDAQ:ELGX shares closed at $7.45 per share.
Those who purchased shares of Endologix, Inc. have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego